Monday, December 8, 2025
Home Tags Alembic Pharmaceuticals

Tag: Alembic Pharmaceuticals

Alembic Pharmaceuticals and Amlan International launch MinerTox-Z and MinerTox-A
Industry & Sector-Specific

Alembic Pharmaceuticals and Amlan International launch MinerTox-Z and MinerTox-A

Author -
0
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
Health/ Lifestyle & Entertainment

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets

Passionate in Marketing -
0
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Extended-Release Tablets.
Branding/Advertising

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Extended-Release Tablets.

Author -
0
Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen U.S. footprint
Business & Finance

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen U.S. footprint

Author -
0
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
News & Reports

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg

Author -
0
Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg.
Branding/Advertising

Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg.

Passionate in Marketing -
0
Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg.
Branding/Advertising

Alembic Pharmaceuticals announces USFDA Tentative Approval for Ivosidenib Tablets 250 mg

Passionate in Marketing -
0
Alembic Pharmaceuticals announces USFDA Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg
Marketing Analytics

Alembic Pharmaceuticals announces USFDA Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg

Passionate in Marketing -
0
Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
Branding/Advertising

Alembic Pharmaceuticals Receives 5 USFDA Product Approvals in Q1FY25

Passionate in Marketing -
0
Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
Marketing Analytics

Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) for its Oncology Formulation Facility at Panelav

Passionate in Marketing -
0
12Page 1 of 2

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

ABOUT US

Passionate in Marketing is promoted by i-miRa Knowledge Solutions, a company founded in 2010 to foster various business units dedicated to creating, disseminating, and managing knowledge-based products, services, and solutions. These offerings cater to corporate entities, startups, and academic institutions alike.

Contact : [email protected]

FOLLOW US

© 2025| Passionate In Marketing |All Rights Reserved | Privacy Policy